Those of you interested in risk and compliance topics working in the pharmaceutical and life science industry will be interested in the latest issue of our dedicated Compliance Newsletter. Every two month my colleague Paul Noble compiles this fine summary of latest news and trends from the FDA, EMA and discusses the implications of recently published warning letters and enforcement actions.
Attached to this post please find the January/February issue. Among other things it takes a look at the new Chinese Tort Law.
If you are interested in a free subscription please let us know - or simply subscribe to the ARIS GRC group.
